The combined approach involves radiofrequency ablation to generate neoantigens and influx of CD8+ T-cells, along with checkpoint inhibitors to activate these CD8+ T-cells to invigorate an antitumour immune response against HCC cells. This evidence concerns the gene CD8A and hepatocellular carcinoma.